Clinical Trial Update: Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating safety and efficacy of BCG combined with tislelizumab in patients with high-risk non-muscle-invasive bladder cancer w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• BCG (Bacillus Calmette-Guérin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Non-muscle-invasive Bladder Cancer | Phase 4 | Status: UNKNOWN